Skip to main content

Table 2 Incidence rates of opportunistic infections according to systemic rheumatic disease

From: Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study

 

SLE (N = 15,961, PY = 89,256)

PM/DM (N = 2270, PY = 10,252)

SSc (N = 2071, PY = 10,868)

RA (N = 38,355, PY = 22,7549)

pSS (N = 18,309, PY = 81,995)

Events

IR (95% CI)

Events

IR (95% CI)

Events

IR (95% CI)

Events

IR (95% CI)

Events

IR (95% CI)

Fungus

 Aspergillus

16

0.18 (0.10–0.29)

6

0.59 (0.22–1.27)

1

0.09 (0.01–0.51)

22

0.10 (0.06–0.15)

5

0.06 (0.02–0.14)

 Candidiasis

388

4.35 (3.93–4.80)

85

8.29 (6.62–10.25)

49

4.51 (3.34–5.96)

426

1.87 (1.70–2.06)

145

1.77 (1.49–2.08)

 Cryptococcus

39

0.44 (0.31–0.60)

9

0.88 (0.40–1.67)

2

0.18 (0.02–0.67)

45

0.20 (0.14–0.27)

14

0.17 (0.09–0.29)

 PJP

45

0.51 (0.37–0.67)

18

1.76 (1.04–2.78)

4

0.37 (0.10–0.94)

18

0.08 (0.05–0.13)

9

0.11 (0.05–0.21)

 Subtotal

488

5.48 (4.99–5.98)

118

11.5 (9.53–13.8)

56

5.15 (3.89–6.69)

511

2.25 (2.06–2.45)

173

2.11 (1.81–2.45)

CMV

100

1.12 (0.91–1.37)

18

1.76 (1.04–2.78)

4

0.37 (0.10–0.94)

29

0.13 (0.09–0.18)

15

0.18 (0.10–0.30)

Salmonellosis

272

3.05 (2.70–3.43)

30

2.93 (1.97–4.18)

11

1.01 (0.51–1.81)

118

0.52 (0.43–0.62)

27

0.33 (0.22–0.48)

Herpes zoster

2580

28.9 (27.8–30.0)

377

36.8 (33.2–40.7)

216

19.9 (17.3–22.7)

4084

17.9 (17.4–18.5)

1502

18.3 (17.4–19.3)

TB

341

3.82 (3.43–4.25)

71

6.93 (5.41–8.74)

47

4.32 (3.18–5.75)

839

3.69 (3.44–3.95)

213

2.60 (2.26–2.97)

NTM

63

0.71 (0.54–0.90)

14

1.37 (0.75–2.29)

9

0.82 (0.38–1.57)

121

0.53 (0.44–0.64)

48

0.59 (0.43–0.78)

Non-herpes zoster infection

1264

14.2 (13.4–15.0)

251

24.5 (21.6–27.7)

127

11.7 (9.74–13.9)

1617

7.10 (6.76–7.40)

476

5.81 (5.30–6.35)

Total

3844

43.1 (41.7–44.5)

628

61.3 (56.6–66.2)

343

31.6 (28.3–35.1)

5701

25.0 (24.4–25.7)

1978

24.1 (23.1–25.2)

  1. Incidence rates (IRs) are reported as the number of cases per 1000 person-years
  2. SLE systemic lupus erythematosus, RA rheumatoid arthritis, pSS primary Sjögren’s syndrome, SSc systemic sclerosis, PM/DM polymyositis/dermatomyositis, PJP Pneumocystis jiroveci pneumonia, CMV cytomegalovirus, TB tuberculosis, NTM non-tuberculosis mycobacterium, PY person-years